title: Reply to C. Fontanella et al.
authors.affiliation: BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium hatem.azim@bordet.be.
authors.forename: Hatem A
authors.initials: HA
authors.lastname: Azim
authors.affiliation: BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Evandro
authors.initials: E
authors.lastname: de Azambuja
authors.affiliation: Frontier Science, Kincraig, Kingussie, Scotland.
authors.forename: Dominique
authors.initials: D
authors.lastname: Agbor-Tarh
authors.affiliation: Frontier Science, Kincraig, Kingussie, Scotland.
authors.forename: Ian
authors.initials: I
authors.lastname: Bradbury
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003967:Diarrhea / Q000139:chemically induced*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines